|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-----Original Message-----
From: Ben Hansen [mailto:heartofbear@hotmail.com]
Sent:
To: jim@psychrights.org; DJRICCIO@aol.com; gracejackson@ncfreedom.net;
heartofbear@hotmail.com; pr@psychrights.org
Subject: FDA Drug Safety and Risk Mgmt Advisory Committee
This web page lists the members of the
Drug Safety and Risk Mgmt Advisory
Committee which voted 8-7 on Feb. 9 for a
black box warning on stimulants.
Toward the bottom of the page, click on
the link "Attention
Deficit/Hyperactivity Disorder Drug
Cardiovascular Adverse Events - February
9" And then at the bottom of THAT page,
see the links to "conflicts of
interest." I learned that committee
member Elizabeth Andrews has ties to
GlaxoSmithKline:
http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/Drug+Safety+and+Risk+Mgmt/default.htm
Drug Safety and Risk Mgmt Advisory
Committee
Committee Roster:
Peter Gross MD,
Stephanie Crawford PhD, University of
Jacqueline Gardner PhD/MPH,
Eric Holmboe MD, American Board of
Internal Medicine
Henri Manasse PhD, American Society of
Health-System Pharmacists
Richard Platt MD,
Annette Stemhagen DrPH, United BioSource
Corporation (Industry
Representative)
Michael Cohen RPh/MS/DSc, Institute for
Safe Medication Practices
Terry Davis PhD,
Eleanor Gomez-Fein PharmD,
Arthur Levin MPH, Center for Medical
Consumers (Consumer Representative)
Louis Morris PhD, Louis A Morris & Assoc.
(
Robyn Shapiro JD,